Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein - paediatric investigation plan
human papillomavirus type 16 L1 protein
human papillomavirus type 18 L1 protein
PIPHuman
Key facts
- Invented name
- Cervarix
- Cervarix
- Active Substance
- human papillomavirus type 16 L1 protein
- human papillomavirus type 18 L1 protein
- Therapeutic area
- Vaccines
- Decision number
- P/11/2009
- PIP number
- Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein
- Pharmaceutical form(s)
- Suspension for injection
- Condition(s) / indication(s)
- Infection by Human Papillomavirus in females
- Route(s) of administration
- Intramuscular injection
- Contact for public enquiries
GlaxoSmithKline Biologicals S.A.
E-mail: [email protected]
Tel.: +1 438 899 8201- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date